---
title: Human and Microbial Determinants of the Onset of IBD Flares
nct_id: NCT06967311
overall_status: RECRUITING
sponsor: Viome
study_type: OBSERVATIONAL
primary_condition: IBD (Inflammatory Bowel Disease)
countries: Brazil
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06967311.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06967311"
ct_last_update_post_date: 2025-06-15
last_seen_at: "2026-05-12T06:33:54.813Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Human and Microbial Determinants of the Onset of IBD Flares

**Official Title:** Microbial and Human Determinants of the Onset of IBD Flares

**NCT ID:** [NCT06967311](https://clinicaltrials.gov/study/NCT06967311)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Viome
- **Collaborators:** Universidade Federal de Santa Catarina
- **Conditions:** IBD (Inflammatory Bowel Disease)
- **Start Date:** 2025-01-31
- **Completion Date:** 2030-02
- **CT.gov Last Update:** 2025-06-15

## Brief Summary

This study will collect longitudinal biological samples and survey data to identify the triggers of IBD flares.

## Detailed Description

This is a longitudinal observational study whose goals are to identify:

Microbial and human molecular triggers of IBD relapses, Microbial and human molecular pathways strongly associated with flares that could be targeted with nutrition with a therapeutic potential, Biomarkers of IBD for Dx purposes, Identify microbial functions associated with release of BH4.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patient at Universidade Federal de Santa Catarina (UFSC) Hospital, under care of Dr. Vivian Menegassi

Exclusion Criteria:

* Cancer Diagnosis/Treatment
* Under 18 years old
```

## Arms

- **Inflammatory Bowel Disease (IBD)** — Individuals diagnosed with IBD

## Primary Outcomes

- **Stool microbial KEGG orthologs (KOs) associated with IBD** _(time frame: For 12 months from enrollment)_ — Metatranscriptomic tests will be used to quantify microbial KOs in stool samples. At the end of the study, we will use machine learning to identify KOs whose expression is associated with IBD.

## Locations (1)

- LABOX, Department of Biochemistry, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brazil — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.labox, department of biochemistry, universidade federal de santa catarina|florianópolis|santa catarina|brazil` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06967311.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06967311*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*